Rivaroxaban [39], the second DOAC approved for AF patients on the basis of the results of the ROCKET AF (The Rivaroxaban One Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial [40], acts as a direct oral factor Xa inhibitor (FXaI) (Figure 1). Here, F10 is linked to stroke disorder.